John Goudreau, DO
Neurology · East Lansing, MINPI 1477563096
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Sage Therapeutics, LLC at 40.2% of the total. Reporting peaked in 2023 at $3,269 and has fallen 89.7% since, to $336 in 2025.
Across 76 payments — averaging $66.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sage Therapeutics, LLC$2K
- UCB, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$659
- AbbVie$286
- Acadia Pharmaceuticals Inc$190
- Amneal Pharmaceuticals LLC$185
- plus $628 from 16 others
Across 56 payments — averaging $5027.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$118K
- Sunovion Pharmaceuticals Inc.$71K
- Amneal Pharmaceuticals LLC$21K
- Sage Therapeutics, LLC$20K
- AbbVie$17K
- Acadia Pharmaceuticals Inc$16K
- plus $20K from 4 others
What the payments were for
- Speaking & faculty fees$591%
- Travel & lodging$2,64652%
- Food & beverage$2,07241%
- Education$2996%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sage Therapeutics, LLC | 5 | $2,042 |
| UCB, Inc. | 8 | $1,087 |
| Teva Pharmaceuticals USA, Inc. | 7 | $659 |
| AbbVie | 14 | $286 |
| Acadia Pharmaceuticals Inc | 4 | $190 |
| Amneal Pharmaceuticals LLC | 11 | $185 |
| Ipsen Biopharmaceuticals, Inc | 2 | $139 |
| Acorda Therapeutics, Inc | 7 | $133 |
| Abbott | 3 | $48 |
| Biogen | 2 | $46 |
| Kyowa Kirin, Inc. | 2 | $34 |
| Argenx US, Inc. | 1 | $34 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Greenwich Biosciences, Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Medtronic | 1 | $17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Aucta Pharmaceuticals, Inc. | 1 | $16 |
| GRT US Holding, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,077 in reported general payments places this provider in the 70th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 65 | $318,675 |
| Austedo XrDeutetrabenazine | 28 | $231,043 |
| RytaryCarbidopa/Levodopa | 101 | $181,745 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 20 | $116,805 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 322 | $29,155 |
| Rasagiline Mesylate | 95 | $20,357 |
| NeuproRotigotine | 12 | $15,938 |
| Ropinirole ErRopinirole Hcl | 30 | $7,538 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 71 | $4,407 |
| Primidone | 60 | $4,350 |
| Selegiline Hcl | 17 | $2,519 |
| AmantadineAmantadine Hcl | 38 | $1,980 |
| Propranolol Hcl ErPropranolol Hcl | 24 | $1,225 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $1,149 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 22 | $948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $190 | $318,67565 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $659 | $231,04328 claims |
| Amneal Pharmaceuticals LLCRytary | $185 | $181,745101 claims |
| UCB, Inc.Neupro | $1,087 | $15,93812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 652 neurology providers in Michigan.
Other neurology in East Lansing
- Amit SachdevEast Lansing$374K
- Tariq GheithEast Lansing$347K
- Larry CharlestonEast Lansing$284K
- Jayne WardEast Lansing$169K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
- Bisena BulicaDetroit$900K
- Julie BurnhamMount Clemens$836K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.